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IL-4 is an anti-inﬂammatory cytokine that inhibits the onset and severity in diﬀerent experimental arthritis models. Group B
streptococci (GBS) have been recognized as an ever-growing cause of serious invasive infections in nonpregnant adults. Septic
arthritis is a clinical manifestation of GBS infection. To investigate the role of IL-4 in experimental GBS infection, IL-4 deﬁcient
or competent mice were inoculated with 1 × 107 GBS/mouse. Mortality, appearance of arthritis, GBS growth in the organs, and
local and systemic cytokine and chemokine production were examined. IL-4–/– mice showed lower mortality rates but increased
severity of arthritis and exhibited a lower microbial load in blood, kidneys, and joints than wt mice. Increased local levels of IL-1
β,I L - 6 ,T N F - α, MIP-1α, and MIP-2 accompanied the more severe arthritis in IL-4–/– mice. Our results suggest a detrimental role
of IL-4 in GBS sepsis, whereas it plays a beneﬁcial eﬀect on GBS-induced arthritis.
Copyright © 2009 Luciana Tissi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Group B streptococci (GBS) have long been known as
a leading cause of life-threatening infection in neonates,
young infants, and pregnant women [1–3]. Recently these
microorganisms have been recognized as an ever-growing
cause of serious invasive infections in nonpregnant adults
[4–6]. GBS is responsible for a wide spectrum of clinical
manifestations [5–9]. The most common entities include
primary bacteraemia, skin and soft tissue infections, urinary
tract infections, and pneumonia. Other relevant conditions
are endocarditis, intravascular device infections, meningitis,
peritonitis, endoophthalmitis and osteoarticular infections.
Bacterial arthritis is a rapidly progressive and highly destruc-
tive joint disease in humans with an incidence rate ranging
from 0.034% to 0.13% [10]. The typical case of this disease
is characterized by high fever and a red, warm, and swollen
joint, in 80% to 90% of cases displaying a monoarticular
pattern. Patients with primary or secondary immunodeﬁ-
ciencies as well as those who have passed through pros-
thetic joint surgery display enhanced susceptibility to septic
arthritis [10–12]. Septic GBS arthritis in nonpregnant adults
was considered extremely rare [13, 14] until the early 1980s,
when two independent studies stressed that its incidence
seemed to be increasing [15, 16]. This trend has been
conﬁrmed by recent studies in which GBS account for 7%
to 10% of all diagnosed cases of bacterial arthritis [17, 18].
Interestingly,GBSweretypicallyassociatedwithinvolvement
of multiple joints in patients with diabetes mellitus or cancer
[17].
We have previously described an experimental mouse
model of type IV GBS infection with clinical features
that closely resemble infection in humans [19, 20]. Mice
given a single intravenous dose of GBS develop clinical
signs of arthritis within 48 hours. Appearance and severity
of GBS arthritis are the by-product of a multifactorial
process. Viability and number of microorganisms injected
and bacterial factors (i.e., presence and amount of capsule,
amount of sialic acid in the capsular polysaccharide, and β-
hemolysin production) have been shown to inﬂuence the
development of articular lesions [21, 22]. Nevertheless, in
the pathogenesis of GBS arthritis a crucial role is played by
inﬂammatory cells (granulocytes and monocytes) that reach
thejoints[23,24]andbytheproductionofproinﬂammatory
cytokines, including interleukin-6 (IL-6) IL-1β and tumor
necrosis factor-α (TNF-α)[ 25].2 Mediators of Inﬂammation
Antiinﬂammatory cytokines such as IL-4 are known to
regulate inﬂammation. Many of the IL-4 regulatory eﬀects
are directed at modulating macrophage activity. IL-4 sup-
presses proinﬂammatory cytokines (TNF-α IL-1β,a n dI L -
12) [26, 27] and chemokines (interferon-γ-inducible protein
10 and macrophage migration inhibitory factor) [28, 29].
The antiinﬂammatory activity of IL-4 was assessed in vivo
in several models of arthritis. It has been demonstrated that
systemic administration of IL-4 eﬀectively suppresses disease
in proteoglycan-induced arthritis (PGIA) and collagen-
induced arthritis (CIA) [30, 31]. Treatment with IL-4 or
local expression of IL-4 in CIA prevents cartilage and bone
destruction [32, 33].
The aim of our study was to assess the role of IL-4 in
our septic arthritis model, both regarding development of
the arthritic process and host susceptibility to bacteria. For
this purpose, we used Balb/c wild-type mice and Balb/c mice
with disrupted IL-4 gene.
2.MaterialsandMethods
2.1. Mice. Homozygotous IL-4−/− mice, generated as
described elsewhere [34], have been kindly provided by
Prof. Luigina Romani, University of Perugia, Perugia, Italy.
Control wt Balb/c mice were purchased from Charles River
Breeding Laboratories (Calco, Italy). Eight-to-ten week old
mice were used for experimental procedures. The animals
were maintained and used under strict ethical conditions
according to recommendations of European Union’s Direc-
tive no. 86/609/EEC.
2.2. Microorganisms. Type IV GBS, ATCC reference strain
GBS 3139 (CNCTC 1/82), supplied by J. Jelinkova (Prague,
Czech Republic) was used throughout the study. For experi-
mental infection, the microorganisms were grown overnight
at 37
◦C in Todd-Hewitt broth (Oxoid Ltd., Basingstoke,
Hampshire, England) and then washed and diluted in RPMI
1640 medium (GIBCO, Life Technologies, Milan, Italy). The
inoculum size was estimated turbidimetrically, and viability
counts were performed by plating on tryptic soy agar −5%
sheep blood agar (blood agar), and overnight incubation
under anaerobic conditions at 37
◦C. A bacterial suspension
was prepared in RPMI 1640 medium. Mice were inoculated
intravenously via the tail vein with 1 × 107 GBS in a volume
of 0.5mL. Control mice were injected by the same route with
0.5mL of RPMI 1640 medium.
2.3. Clinical Evaluation of Arthritis and Mortality. GBS-
infected mice were evaluated for signs of arthritis and for
mortality. Mortality was recorded at 24-hour intervals for
30 days. After challenge, mice were examined daily by
two independent observers (L. T., M. P.) for 30 days to
evaluate the presence of joint inﬂammation, and scores
for arthritis severity (macroscopic score) were given as
previously described [26, 35]. Arthritis was deﬁned as visible
erythema and/or swelling of at least one joint. Clinical
severity of arthritis was graded on a scale of 0–3 for each
paw, according to changes in erythema and swelling (0 = no
change; 1 point = mild swelling and/or erythema; 2 points =
moderateswellinganderythema;3points=markedswelling,
erythema, and/or ankylosis). Thus, a mouse could have a
maximum score of 12. The arthritis index (mean ± SD) was
constructed by dividing the total score (cumulative value of
allpaws)bythenumberofanimalsusedineachexperimental
group.
2.4. Histological Assessment. GBS-infected mice were exam-
ined 10 days after infection for histopathological features of
arthritis. Arthritic hind paws (1 per mouse) were removed
aseptically, ﬁxed in formalin 10%v/v for 24 hours and
then decalciﬁed in trichloroacetic acid 5%v/v for 7 days,
dehydrated, embedded in paraﬃn, sectioned at 3-4μm, and
stained with hematoxylin and eosin. Samples were examined
under blinded conditions. Tibia-tarseal, tarsus-metatarseal,
and metatarsus-phalangeal joints were examined, and a
histologicscorewasassignedtoeachjointbasedontheextent
of inﬁltrate (presence of inﬂammatory cells in the subcu-
taneous and/or periarticular tissues), exudate (presence of
inﬂammatory cells in the articular cavity), cartilage damage,
bone erosion, and loss of joint architecture. Arthritis severity
was classiﬁed as negative (no inﬁltrate), mild (minimal
inﬁltrate),moderate(presenceofinﬁltrate,minimalexudate,
and integrity of joint architecture), and severe (presence of
massive inﬁltrate/exudate, cartilage and bone erosion, and
disrupted joint architecture).
2.5. GBS Growth in Blood, Kidneys, and Joints. Blood, kidney
and joint bacterial load in GBS-infected mice was deter-
mined by colony-forming-units (CFU) evaluation at diﬀer-
ent times after inoculation. Blood samples were obtained by
retroorbital sinus bleeding before the mice were killed. Ten-
fold dilutions were prepared in RPMI 1640 medium, and
0.1mL of each dilution was plated in triplicate on blood
agar and incubated under anaerobic conditions for 24 hours.
The number of CFU was determined, and the results were
expressed as the number of CFU per mL of blood. Kidneys
were aseptically removed and homogenized with 3mL of
sterile RPMI 1640. All wrist and ankle joints from each
mouse were removed, weighed, and homogenized in toto in
sterile RPMI 1640 medium (1mL/100mg of joint weight).
After homogenization, all tissue samples were diluted and
plated in triplicate on blood agar, and the results were
expressed as the number of CFU per whole organ or per ml
of joint homogenate.
2.6. Sample Preparation for Cytokine Assessment. Blood sam-
plesfromthediﬀerentexperimentalgroupswereobtainedby
retroorbital sinus bleeding at diﬀerent times after infection
before the mice were killed. Sera were stored at −80
◦C
until analyzed. Joint tissues were prepared as previously
described [25]. Brieﬂy, all wrist and ankle joints from each
mouse were removed and then homogenized in toto in
1mL/100mg joint weight of lysis medium (RPMI 1640 con-
taining 2mM phenylmethylsulfonyl ﬂuoride and 1μg/mL
ﬁnalconcentrationofaprotinin, leupeptin, andpepstatinA).
The homogenized tissues were then centrifuged at 2000gMediators of Inﬂammation 3
for 10 minutes, and supernatants were sterilized using a
Milliporeﬁlter(0.45μm)andstoredat−80
◦Cuntilanalyzed.
2.7. Cytokine Assays . IL-6, IL-1β,T N F - α,m a c r o p h a g e
inﬂammatory protein (MIP)-1α, and MIP-2 concentrations
in the biological samples were measured with commercial
ELISA kits purchased from R&D System (R&D Systems Inc.,
Minneapolis, Minn, USA) according to the manufacturer’s
recommendations. Results were expressed as picograms per
mL of serum or supernatant from joint homogenates. The
detection limits of the assays were 1.6pg/mL for IL-6,
3pg/mL for IL-1β,1 . 5 p g / m Lf o rM I P - 1 α,1 . 5 p g / m Lf o r
MIP-2, and 5.1pg/mL for TNF-α.
2.8. Statistical Analysis. Diﬀerences in the arthritis index,
number of CFU, and cytokine concentrations between the
groups of mice were analyzed by Student’s t-test. The
log-rank test was used for data analyses of Kaplan-Meier
survival curves. Incidence of arthritis and histologic data
were analyzed by Fisher’s exact test. Each experiment was
repeated 3 times. P-values less than .05 were considered
signiﬁcant.
3. Results
3.1. IL-4 Deﬁciency Decreases Mortality But Increases Severity
ofGBS-InducedArthritis. Balb/cmicedefective(IL-4−/−)or
intact (wt) with respect to IL-4 gene were injected I.V. with
1 × 107 GBS and the clinical course of disease was followed
up to 30 days. The severity of the disease was monitored by
assessing both survival rates and clinical score of arthritis.
As shown in Figure 1(a) statistically signiﬁcant (P = .0372)
diﬀerences were observed in mortality rates between the
two experimental groups. In fact, infection with 107 GBS
per mouse resulted in a 10% mortality in IL-4−/− mice,
while 40% of wt mice had died at the end of observation
period. The clinical signs of joint swelling were observed as
early as 24 hours after injection of 1 × 107 CFU of GBS in
both groups of mice. Although similar frequency of articular
lesions was observed in IL-4−/− and wt mice (Figure 1(b)),
IL-4 deﬁcient group had a more severe clinical arthritis in
aﬀected joints, compared with the control animals, resulting
in a higher arthritis index (Figure 1(c)). Signiﬁcant between-
group diﬀerences were evident throughout the observation
period, with maximum values reached at day 10 after
infection of 3.2 ± 0 . 5i nI L - 4 −/− mice versus 2.0 ± 0.3 in
wt animals.
3.2. Histopathological Findings. Arthritic paws were removed
for histological examination at day 10 after infection with 1
× 107 GBS per mouse and examined for histopathological
features of arthritis. Five arthritic paws from both IL-4−/−
mice and BAlb/c mice were removed, and 3 joints for each
paw were assessed for histopathological score. Two separate
experiments were performed and results were cumulated.
As shown in Figure 2,n o n eo ft h ej o i n t sf r o mc o n t r o l
animals could be classiﬁed as severely aﬀected. In this group,
39% of the joints were classiﬁed as mildly aﬀected, 32%
P = .0372
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Figure 1: Mortality rates, incidence, and severity of arthritis. IL-4-
deﬁcient and wt mice were infected with 107 GBS/mouse. Mortality
(a), incidence (b), and severity (c) of arthritis were evaluated as
detailed in materials and methods (see Section 2). Ten mice were
used in each experimental group. (a) The data are the cumulative
results of three separate experiments. (b) and (c) Data represent
the mean ± SD of three separate experiments. Statistical diﬀerences
between the experimental groups were marked with asterisk (P<
.05).4 Mediators of Inﬂammation
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Figure 2: Histopathological ﬁndings. Histophatolgical severity of
arthritis was assessed in IL-4−/− mice or controls 10 days after
infection. Arthritis was deﬁned negative, mild moderate, or severe
as detailed in Materials and Methods (see Section 2). Cumulative
results of two independent experiments are represented. For each
experimental group, 5 arthritic paws from IL-4−/− mice or control
mice were removed, and 3 joints for each paw were assessed for
histopathological score.
as moderately aﬀected, and 29% did not show any sign of
arthritis. In contrast, In IL4−/− mice only 5% of the joints
were negative, while the majority of them were classiﬁed as
moderately (49%) or severely (31%) aﬀected.
3.3. Lower Bacterial Growth in IL-4−/− Mice. In vivo GBS
growth was assessed 2, 5, and 10 days after GBS infection by
quantitative monitoring of bactaeremia and bacterial growth
in kidneys and joints of IL-4−/− or wt mice. As shown in
Figure 3,ap r o g r e s s i v ec l e a r a n c eo fb a c t e r i aw a so b s e r v e di n
the blood of wt as well as IL-4−/− animals. However, it is
noteworthy that a signiﬁcantly (P<. 05) lower number of
GBS were recovered in the bloodstream of IL-4−/− mice in
comparison to controls, as soon as two days after infection.
Such a signiﬁcant diﬀerence was still evident in the following
days. A lower streptococcal growth was also observed in
the kidneys from IL-4−/− mice with respect to controls.
Ten-fold between-group diﬀerences in the number of GBS
recovered were found at all the time points assessed. Finally,
as already assessed in the kidneys and in the blood, bacterial
burden in the joints of IL-4−/− mice was signiﬁcantly
lower than in controls, as soon as 2 days after infection. A
progressive bacterial growth was then observed in the joints
of both experimental groups, although a signiﬁcantly lower
bacterial load was still present in IL-4−/− mice.
3.4. IL-4 Deﬁciency Gives Rise to Upregulation of Local
Cytokine and Monokine Production. The role played by
cytokines and monokines on the pathogenesis of GBS sepsis
andarthritisiswell-deﬁned[24,25].Thus,localandsystemic
levels of IL-6, IL1β,T N F - α,M I P - 1 α,a n dM I P - 2w e r e
compared between IL-4−/− and control mice at 2, 5, and
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Figure 3: Bacterial growth in blood, kidneys and joints. IL-4-
deﬁcient and wt mice were infected with 1 × 1076 GBS/mouse,
and blood and organs were removed and processed as detailed in
materials and methods (see Section 2). The values represent the
mean ±SDofthreeseparateexperimentseachconsistingof20mice
per experimental group. Three mice per group were sacriﬁced at
each time point. Results are expressed as number of CFU per ml of
blood, per whole organ, or per ml of joint homogenate. Statistical
diﬀerences between the experimental groups were marked with
asterisk (P<. 05).Mediators of Inﬂammation 5
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Figure 4: Cytokine production in joints, and sera. IL-4-deﬁcient or wt mice infected with 1 × 107 GBS/mouse. Supernatants from joint
homogenates, or blood samples were collected at the indicated times after infection and assayed for TNF-α, IL-6, and IL-1β by ELISA as
detailed in materials and methods (see Section 2). Values are the mean ± SD of three separate experiments each consisting of 20 mice per
experimental group. Three mice per group were sacriﬁced at each time point. Statistical diﬀerences between the experimental groups were
marked with asterisk (P<. 05).6 Mediators of Inﬂammation
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Figure 5: Chemokine production in joints. IL-4-deﬁcient or wt mice infected with 1 × 107 GBS/mouse. Supernatants from joint homogenates
were collected at the indicated times after infection and assayed for Mip-1α and MIP-2 by ELISA as detailed in materials and methods (see
Section 2).Valuesarethemean ±SDofthreeseparateexperiments each consistingof20miceperexperimental group.Threemicepergroup
were sacriﬁced at each time point. Statistical diﬀerences between the experimental groups were marked with asterisk (P<. 05).
10 days after infection. As depicted in Figure 4, higher levels
of proinﬂammatory cytokines (IL-6, IL1β and TNF-α)w e r e
detected in the joints of IL-4−/− mice than in controls. At
day 2 after infection signiﬁcantly higher levels were evident
only with regard to TNF-α production, but at the other time
points assessed diﬀerences became statistically signiﬁcant
also for IL-6 and IL-1β production. On the contrary, serum
levels of proinﬂammatory cytokines were similar in both
groups,exceptforTNF-α production whichwas signiﬁcantly
higher in IL-4−/− mice with respect to controls (52 ± 10
versus 11 ± 5pg/mL of serum) at day 2 after infection. A
similar trend was observed for MIP-2 and MIP-1 production
in both groups of mice, with peak values reached at day
5 after infection. Again, signiﬁcantly higher levels of both
chemokines were detected in the joints of IL-4−/− mice
than in wt animals at all the time points assessed (Figure 5).
Diﬀerently from the joints, no signiﬁcant diﬀerences were
observed between the two experimental groups with respect
to systemic production of MIP-1α and MIP-2 (data not
shown).
4. Discussion
The murine model of GBS infection has proven to be bene-
ﬁcial in elucidating bacterial and host factors responsible for
GBS arthritis [19–25]. Our previous studies pointed out a
major role for proinﬂammatory cytokines such as of IL-6,
IL-1β, IL-18, and TNF-α in the pathogenesis of GBS arthritis
[25, 36]. In this study, by using deﬁcient mice, we found that
the antiinﬂammatory cytokine IL-4 has a relevant inﬂuence
on GBS-induced sepsis and septic arthritis. The ﬁrst eﬀect of
IL-4 absence on the course of GBS infection is the decrease
of mortality rates. This result is in line with a paper by
Hultgren et al., who described a beneﬁcial eﬀect of IL-4 lack
in an experimental murine model of Staphylococcus aureus
infection [37]. In this paper, the diminished mortality rates
observed in IL-4−/− mice were associated to an increased
systemic bacterial clearance, attributable to an enhanced
intracellular killing capacity mediated by phagocytic cells.
It has been demonstrated that IL-4 acts on phagocytes
by suppression of oxidative bursts and intracellular killing
of Leishmania [38], and inhibits peritoneal and splenic
macrophage killing of Candida albicans [39]. Actually, in our
experimental model a lower number of GBS were recovered
both from blood and kidneys of IL-4−/− mice compared to
controls, thus suggesting that IL-4 exerts an inhibitory eﬀect
also on GBS killing by phagocytes.
Lack of IL-4 also results in a worsening of articular
lesions. This was apparently in contrast with the lower bacte-
rial load found in the joints of IL-4−/− mice with respect to
controls.However,itmustbeconsideredthatseverityofGBS
arthritis is not exclusively linked to the amount of bacteria
present in the joints, but is also dictated by other parameters,
including proinﬂammatory cytokine production and the
extent of inﬂammatory inﬁltrate/exudates in the articular
tissues. The recruitment and activation of inﬂammatory cells
at infection sites is a complex and dynamic process that
involves the coordinated expression of both pro- and anti-
inﬂammatory mediators. Indeed, although an inﬂammatory
response is essential to clear pathogens from the site of
infection, a prolonged inﬂammatory response might lead to
adetrimentalout c ome[35].Inthisrespect,abeneﬁcialeﬀect
of IL-4 has been demonstrated in many experimental model
of arthritis. Administration of exogenous IL-4 resulted in
suppression of CIA [30], while, in the same experimental
model, administration of anti-IL4 monoclonal antibodies
augmented both incidence and severity of arthritis [40].
Daily treatment with IL-4 was reported to reduce all disease
parameters in a streptococcal cell wall (SCW) rat arthritis
model [41]. In the PGIA model, arthritis was prevented byMediators of Inﬂammation 7
IL-4 treatment [31]a n de x a c e r b a t e di nI L - 4 −/− mice [27].
In these mice, the rapid induction of arthritis parallels in
vivo increase of proinﬂammatory cytokine and chemokine
secretion. It is well known that proinﬂammatory cytokines
and chemokines play a critical role in the pathogenesis of
arthritis. Resident synovial macrophages and ﬁbroblasts as
well as inﬁltrate cells produce proiﬂammatory cytokines,
such as TNF-α, IL-1, IL-6, IL-15, and IL-17 that drive disease
pathogenesis [42, 43]. These cytokines initiate a cascade
of events that induce cartilage-degrading enzymes, such as
metalloproteases, and that stimulate osteoclastogenesis and
angiogenesis [44–46]. Recruitment of cells to the synovial
tissues involves chemokines, such as MIP-1α, responsible for
r e c r u i t m e n to fm o n o n u c l e a rc e l l sa n dM I P - 2t h a ta c t so n
neutrophils. All these inﬂammatory cells contribute to artic-
ular damage by cytokine and proteolytic enzyme production
[11]. In our model, despite the lower number of GBS in the
joints of IL-4−/− mice, all the other parameters leading to
an exacerbation of articular lesions are manifested. In fact,
worsening of joint disease was associated with a marked
increase of local proinﬂammatory cytokines (IL-6, IL-1β,
and TNF-α) responsible for articular damage, together with
sustained levels of monokines and a consequent enhanced
inﬂammatory cell inﬂux.
In conclusion, we propose that IL-4 plays a dual role
in the immune response to GBS infection. By one side, by
inhibiting the intracellular killing of phagocytes, IL-4 may
cause a more severe systemic infection and, consequently,
higher mortality rates. By the other side, by downregulating
local levels of proinﬂammatory cytokines and chemokines,
it appears to positively inﬂuence the progression of GBS
arthritis.
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